Sagimet Shares Fall as $115M Offering Closes, Acne Drug Data Digested
SGMT has more than doubled off its 52-week low of $4.5.
Summary
Sagimet Biosciences finalized its underwritten public offering, securing approximately $115 million in gross proceeds. This substantial capital raise, which follows yesterday's pricing announcement, will fund denifanstat's pre-launch activities and its upcoming US Phase 3 trial. Despite positive 52-week open-label extension data for denifanstat in acne, reported yesterday by partner Ascletis Pharma (ASCLF), Sagimet's stock closed down, suggesting the market is digesting the dilutive impact of the offering alongside the clinical results.
At the time of this announcement, SGMT was trading at $9.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $577.1M. The 52-week trading range was $4.50 to $11.45. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.